Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-30

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A new research paradigm that involves sequencing tumor DNA/RNA to identify driver mutations, select among the Health Canada approved drugs (for adult cancers) known to block certain oncogenic pathways, and recommend these drugs to the treating physician, without taking into account the tumor histology.

In this paradigm, the treatment is targeted to the actionable mutation(s) i.e. those driving oncogenesis. It is also personalized to the molecular signature of the patient's tumor, irrespective of its histopathological subtype. The experience of the investigators team in genomics, including next generation sequencing and bioinformatic analysis combined with the clinical expertise, bring at last this approach within our technical capacities. In parallel, the number of Health Canada-approved drugs (which have been tested in a pediatric setting) designed to interfere with oncogenesis pathways is increasing exponentially.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

NCT00024284

Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE1

Irinotecan in Treating Children With Refractory or Progressive Solid Tumors

NCT00016861

Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE1

Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

NCT00004919

Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE1

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

NCT00138216

Brain and Central Nervous System Tumors Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE1

Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling

NCT02613962

Relapsed or Refractory Pediatric Tumor

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

At the time of enrollment:

* 21 year-old or less
* Poor prognosis biopsy-proven cancer of any type :
* Cancer (at initial diagnosis) known to be refractory to treatment
* Or cancer refractory to treatment
* Or relapsed cancer
* Written informed consent by patient, parents, or the legal guardians